US Bancorp’s Bolt Biotherapeutics BOLT Stock Holding History

US Bancorp’s Portfolio BOLT Stock Details BOLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-12	Closed	-$3K	–	4100
2021 Q3	$3K	Buy	+12	New	+$3.39K	﹤0.01%	3763

Other funds holding BOLT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

US Bancorp's BOLT Position: Q4 2021 in Review

US Bancorp sold out of Bolt Biotherapeutics (BOLT) in Q4 2021, closing a stake of 12 shares — an estimated $3K sold.

US Bancorp first reported a position in BOLT in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 62 funds tracked by Wall St. Rank hold BOLT as of Q4 2021.

US Bancorp reported no remaining Bolt Biotherapeutics position as of Q4 2021 after selling out during the quarter.
US Bancorp sold 12 Bolt Biotherapeutics shares in Q4 2021, an estimated $3K.
US Bancorp first reported a position in Bolt Biotherapeutics in Q3 2021 and held it in 1 quarter.
US Bancorp's Bolt Biotherapeutics position peaked at $3K in Q3 2021.
62 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q4 2021.

Based on US Bancorp's 13F filing for Q4 2021, filed 11 Feb 2022.